Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...